This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health Announces Positive Results From Large Study Of Oncotype DX® To Quantify Risk Of Loco-Regional Recurrence In Node-positive Breast Cancer Patients And Acceptance Of Oncotype DX DCIS Validation Study For Publication

"Previous studies have shown the value of Oncotype DX in predicting chemotherapy benefit in both node-negative and node-positive breast cancer. Based on the results presented by Dr. Mamounas, we now have evidence suggesting the value of the Oncotype DX result in tailoring the intensity and extent of radiation in breast cancer patients with node-positive disease," said Steven Shak, M.D., chief medical officer and executive vice president for research and development at Genomic Health.  "This study, combined with an upcoming publication in DCIS, demonstrates our continued efforts in helping physicians and breast cancer patients answer important treatment decision questions about the intensity of their radiation therapy." 

The parent NSABP B-28 trial was funded by the National Cancer Institute with additional support from Bristol Myers Squibb. The study evaluating the prognostic impact of the 21-gene Recurrence Score on loco-regional recurrence was funded through a grant from the Susan G. Komen for the Cure Foundation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of December 31, 2012, more than 10,000 physicians in over 70 countries had ordered approximately 335,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, To learn more about Oncotype DX tests, visit: and

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to  the ability  of the  company's Oncotype DX test to predict loco regional recurrence in node positive breast cancer patients and the potential ability of the  test to be used in  radiation treatment decisions; the applicability of clinical study results to actual outcomes; the scope, success or results of clinical trials and the timing of such activities; the ability of the test to impact clinical practice ; the expectations and timing for the publication of the DCIS validation study; the ability of the company to develop additional tests in the future; the attributes and focus of the company's product pipeline; the potential economic benefits associated with the company's tests; and the demand for the company's tests. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical studies ; the applicability of clinical study results to actual outcomes; the risks and potential delays associated with such studies ;  the risks and uncertainties associated with publication of  the DCIS validation study;  the risks and uncertainties associated with possible additional regulation of the company's tests both in the United States and abroad;; the risks associated with competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.  

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs